What is the present valuation and projected CAGR of the gastric cancer market?
The gastric cancer market size has grown rapidly in recent years. It will grow from $3.17 billion in 2024 to $3.65 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to rising geriatric population, increasing healthcare awarness, increasing genetic mutations, rising adoption of unhealthy lifestyles, growing awarness about cancer.
The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to increasing obesity, growing government initiatives, increasing healthcare investments, rising demand for oral drugs, increasing number of cancer treatment facilities. Major trends in the forecast period include combination chemotherapy, product expansion, robotic-assisted surgery, targeted therapies, strategic collabration, advanced diagnostic tools.
Get Your Free Sample of The Global Gastric Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp
What key drivers have fueled the gastric cancer market’s development over the years?
The rising obesity rates are expected to propel the growth of the gastric cancer market going forward. Obesity is a medical condition characterized by excessive body fat accumulation, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health problems. Obesity rates are rising due to factors such as poor diet, lack of physical activity, sedentary lifestyles, environmental influences, and genetic predispositions. Excess body fat, particularly visceral fat around the abdomen, is associated with a higher risk of developing gastric cancer as obesity triggers chronic inflammation and metabolic disturbances, both linked to cancer development, contributing to a rise in the demand for gastric cancer treatment. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 1 in 8 people globally were living with obesity in 2022, with 2.5 billion adults aged 18 and older classified as overweight, including 890 million individuals living with obesity. Among adults, 43% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight, while over 390 million children and adolescents aged 5–19 years were overweight, including 160 million living with obesity. Therefore, the rising obesity rates are driving the gastric cancer market.
What is the segmentation for the gastric cancer market?
The gastric cancer market covered in this report is segmented –
1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis
3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report
Who are the most influential companies in the gastric cancer market?
Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.
What are the top industry trends projected to impact the gastric cancer market?
Major companies operating in the gastric cancer market are focusing on developing technologically advanced solutions, such as companion diagnostic assays, to help ensure personalized treatment. A companion diagnostic assay is a test used to identify patients who are most likely to benefit from a specific therapeutic treatment based on the presence of certain biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. This assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18.2. Utilizing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, the test advances personalized healthcare, expanding treatment options for gastric and GEJ adenocarcinoma.
What are the major regional insights for the gastric cancer market, and which region holds the top position?
North America was the largest region in the gastric cancer market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Gastric Cancer Market Report 2025 Offer?
The gastric cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Gastric cancer is a malignant tumor that originates in the lining of the stomach. It often begins in the mucosa, the innermost layer of the stomach, and can spread to deeper layers, nearby tissues, or distant organs if not treated early. The disease is commonly associated with risk factors such as chronic infection with helicobacter pylori, smoking, excessive alcohol consumption, poor diet, and genetic predisposition.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
